Esperion Hosting Virtual Research & Development Day
October 27, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 19, 2022 16:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on October 18, 2022, the Compensation Committee of Esperion’s Board of Directors granted 5 new...
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
October 17, 2022 08:02 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on...
Esperion to Participate in Upcoming September Investor Conferences
August 30, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20th Annual Global Healthcare...
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
August 26, 2022 08:16 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04, 2022 16:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new...
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
August 02, 2022 07:00 ET
|
Esperion Therapeutics, Inc.
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
July 25, 2022 15:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB...
Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
July 12, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 12, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2022 financial results before the open of the U.S. financial markets on...
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
June 03, 2022 12:30 ET
|
Esperion Therapeutics, Inc.
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE...